The S-REAL Study: Spanish Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy
Ana Gómez Rueda,Álvaro Taus, Álvarez,Reyes Bernabé-Caro,Luis Chara,Marta López-Brea,Laia Vilà,Maria Ángeles Sala González, Anabel del Barrio Díaz Aldagalán, Beatriz Esteban Herrera,Rafael López Castro,Ruth Álvarez Cabellos,Marta Doménech,Sandra Falagan, Alberto Moreno Vega,Carlos Aguado,Andrés Barba, Maria Teresa Delgado Ureña,Dolores Isla,Lorena Bellido Hernández,José Luis Fírvida Pérez,Óscar Juan-Vidal,Bartomeu Massutí,Xabier Mielgo-Rubio,Ana Laura Ortega,Silvia Catot,Manuel Dómine, Corina Escoín-Pérez,Francisco García Navalón, Ignacio Gil-Bazo,Silvia Muñoz,Delvys Rodríguez-Abreu, Rosa María Villatoro Roldán,Guillermo Alonso-Jáudenes Curbera,Luis León-Mateos,Airam Padilla,Alfredo Paredes Lario,José Miguel Sánchez-Torres,Pilar Garrido CLINICAL & TRANSLATIONAL ONCOLOGY（2024）
Key words
NSCLC,Durvalumab,Chemoradiotherapy,PD-L1,PFS,Real-world
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper